PROGRAM - Malmö kongressbyrå

Nordic Stroke 2015
18th Nordic Congress on Cerebrovascular Diseases
26-28 August 2015 • Malmö, Sweden
PROGRAM
www.nordicstroke.se
Meaningful
Change
Together
Medtronic trademarks are trademarks of a Medtronic company. COVIDIEN, COVIDIEN with logo and the Covidien logo are U.S. and
CONTENTS
CONTENTS
Organisation for the 18th Nordic Congress on Cerebrovascular Diseases
3
Welcome to the 18th Nordic Congress on Cerebrovascular Diseases
5
General information
6
Social program
7
Exhibition area
8
Exhibitor list
9
Program
10-14
Posters
16-17
LOCAL ORGANISING COMMITEE SCIENTIFIC COMMITTEE
Arne Lindgren (chair)
Christina Brogårdh
Irina Dragancea
Ann-Cathrin Jönsson
Bo Norrving
Jesper Petersson
Grethe Andersen, Denmark
Eivind Berge, Norway
Hanne Christensen, Denmark
Per Olof Hansson, Sweden
Bent Indredavik, Norway
Dalius Jatuzis, Lithuania
Janika Kõrv, Estonia
Evija Miglane, Latvia
Karsten Overgaard, Denmark
Jukka Putaala, Finland
Tiina Sairanen, Finland
Katharina Stibrant Sunnerhagen, Sweden
Per Wester, Sweden
Mia von Euler, Sweden
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
3
EXPECT THE BEST OF ALL WORLDS
FROM YOUR LEFT ATRIAL APPENDAGE OCCLUDER
Patienters anatomi av vänster förmaksöra har alla tänkarbara former och storlekar
precis som ett device för stroke-prevention bör ha. AMPLATZER™ Amulet™ left
atrial appendage occluder är designad för komplett förslutning av öppningen till
vänster förmaksöra med bättre kontroll och minimalt antal steg. Den proximala
positioneringen med flexibel nitinol design syftar till att passa olika LAA storlekar
och kan repositioneras eller återhämtas vilket krävs för optimal placering.
Besök www.sjm.com/Amulet för att lära mer om hur AMPLATZER™
teknologin gör Amulet devicet det självklara valet för LAA occlusion.
CAUTION: Device not available in the United States. Product referenced is approved for CE Mark. Device depicted may not be available in all
countries. Check with your St. Jude Medical representative for product availability in your country.
Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications,
warnings, precautions, potential adverse events and directions for use. Unless otherwise noted, ™ indicates that the name is a trademark
of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL and the nine-squares symbol are trademarks and service
marks of St. Jude Medical, Inc. and its related companies. © 2014 St. Jude Medical, Inc. All Rights Reserved.
EM-AMU-0215-0015 | This document is for international use only.
WELCOME
Dear friends and colleagues,
On behalf of the organising committee and the Nordic Stroke Society, it is
my great pleasure to welcome all of you to the 18th Nordic Congress on
Cerebrovascular Diseases, Malmö, Sweden, August 26-28, 2015. Also a great
welcome to our friends and colleagues from Korea who have successfully
contributed and participated in the past Nordic Congresses and continue to
take an active part in our Congress.
Since the previous, very successful meeting in Vilnius, Lithuania in 2013,
numerous new advances have been made within the cerebrovascular field
including prevention, acute stroke care, post stroke care, rehabilitation
and basic sciences. It is therefore very timely for us to meet in Malmö and
discuss and update our opinion on how these new advances affect the
clinical everyday situation from a Nordic viewpoint. The program is exciting
and covers most perspectives on cerebrovascular disease. We are very
happy that we have been able to include so many valuable and important
up-to date presentations on stroke with many well-known international
experts on stroke. You will all have the opportunity to take part in plenary
sessions, workshops, free communications, a poster session as well as social
events.
In August the Nordic summer usually offers a delightful weather and
before and after the conference, there are good opportunities to discover
the wonderful nature and cultural sights of nearby areas in Sweden and
Denmark including the University town of Lund and Copenhagen.
The Nordic Congress on Cerebrovascular Disease has a history of being
warm and welcome and providing excellent opportunities to exchange and
obtain knowledge and experience on stroke and cerebrovascular diseases.
We in the organising committee will do our very best to continue this
tradition of a combination of hospitality, friendship and science and look
very much forward to a successful conference in Malmö. We hope you will
enjoy the Congress and wish you a very pleasant stay in Malmö.
Warmly welcome to the 18th Nordic Congress on Cerebrovascular Diseases,
Arne Lindgren Chair of the 18th Nordic Congress on Cerebrovascular Diseases
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
5
GENERAL
GENERAL INFORMATION
INFORMATION
NAME BADGE
Name badge must be worn at all times during the congress to ensure access
to all sientific sessions and the exhibition area.
MEALS
Coffee and lunch breaks are included in the the registration fee and will be
provided within the exhibition area.
INTERNET
Free access for all delegates in the congress area with the network
”Malmömässan Open”.
POSTER VISIT
Poster visit 27th of August at 15.30-16.15.
SPEAKERS SERVICE CENTER
Give your presentation to the technician in speakers service center in room
5. Preferably in the morning of the day of your talk, but no later than two
hours before your presentation.
MOBILE PHONES
Mobile phones must be in silent mode during the sessions.
TAXI
Taxi Skåne
Taxi Kurir
+46 (0)40 330 330
+46 (0)40 70 000
VENUE
Malmö Mässan
Mässgatan 6
215 32 Malmö, Sweden
CONFERENCE AGENCY
During the conference you will find staff from Malmö Conference Agency at
the registration desk.
Project Manager Ola Nilsson
[email protected]
+46 733 20 20 10
6
Hotels & Delegates
Sofie Welander
[email protected]
+46 729 75 26 22
Malmö Kongressbyrå (PCO)
Norra Vallgatan 16
211 25 Malmö, Sweden
www.mkon.se
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
SOCIAL PROGRAM
WELCOME RECEPTION
Welcome to the the exhibition area at Malmö Mässan. You will be served a
light meal with beverages. Pre registration is required.
When: 26th of August, at 19.30
Dresscode: Informal
CONGRESS DINNER
In the most beautiful parts of Malmö you will find our restaurant Glasklart.
You will be served a three course dinner. The spectacular venue has a ceiling
height of 38 meter and a glass facade towards the sea.
Observe, non alcoholic drinks are included in the fee. Alcoholic beverages
can be purchased during the welcome drink.
To attend the dinner, pre registration is required.
When: 27th of August, at 19.30
Where: Glasklart, Dockplatsen 1, Malmö
Dresscode: Jacket/Semi Formal
Buses from & to Glasklart:
Leave from Malmö Mässan (address, Mässgatan 6, Malmö) at 19:15.
Return from Glasklart to Malmö Mässan at 22.15 and 22.45.
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
7
Hyllie Vattenparksgata
EXHIBITON
AREAAREA
& FLOOR PLAN
EXHIBITION
Hyllie
Trainstation
8
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
EXHIBITOR LIST
NUMERICAL ORDER
1 Stryker
2 Scandinavian Medical Sweden AB
3 St. Jude Medical Sweden AB
4 Covidien Sverige AB a Medtronic Company
5 Boehringer Ingelheim AB
6 Bayer AB
7 CampScandinavia AB
8 EPS Vascular AB
9 Neuravi
10 Zenicor Medical Systems AB
11 Ottobock Scandinavian Group
12 Pfizer and Bristol-Myers-Squibb
13 SITS International
14 Effects-studien
15 Embreis AB
ALPHABETICAL ORDER
Bayer AB
Boehringer Ingelheim AB
CampScandinavia AB
6
5
7
Covidien Sverige AB a Medtronic Company 4
Effects-studien
14
Embreis AB
15
EPS Vascular AB
8
Neuravi
9
Ottobock Scandinavian Group
11
Pfizer and Bristol-Myers-Squibb 12
Scandinavian Medical Sweden AB 2
SITS International
13
St. Jude Medical Sweden AB
3
Stryker
1
Zenicor Medical Systems AB
10
EXHIBITON
& FLOOR26
PLAN
PROGRAM -AREA
WEDNESDAY
AUGUST
Sal 1
09.00-10.45 Registration
10.45-11.00 Welcome Address
Arne Lindgren, Lund
Dalius Jatuzis, Vilnius
11.00-12.30 Plenary session
Endovascular therapy in acute ischemic stroke
Chairs: Nils Wahlgren, Stockholm; Arne Lindgren, Lund
Current evidence from randomised trials (20 + 2 min)
Heinrich Mattle, Bern
Techniques for endovascular treatment (10 + 2 min)
Staffan Holmin, Stockholm
The Aarhus experience of endovascular therapy (10 + 2 min)
Grethe Andersen, Aarhus
The roadmap for implementation of endovascular stroke therapy in Sweden
(10 + 2 min)
Nils Wahlgren, Stockholm
What’s special about basilar artery occlusion? (10 + 2 min)
Perttu Lindsberg, Helsinki
General discussion (20 min)
12.30-14.00 Lunch
Satellite symposium 12.55-13.55
Stroke prevention challenges in AF
Sponsored by St. Jude Medical
Chair: Mårten Rosenqvist, Stockholm; Derk W. Krieger, Copenhagen
AF and stroke – current knowledge and future challenges (18 + 2 min)
Per Wester, Umeå
Use of antithrombotics among ICH survivors (18 + 2 min)
Sören Paaske Johnsen, Aarhus
Left Atrial Appendage Occlusion after ICH (18 + 2 min)
Jens Erik Nielsen Kudsk, Aarhus
14.00-15.30 Plenary session
Joint Session of the Korean and Nordic Stroke Societies on Intracerebral
Hemorrhage
Chairs: Byung-Chul Lee, Seoul; Mia von Euler, Stockholm
Epidemiology and risk factors for ICH in Asian and European populations
(13 + 2 min)
Hee-Joon Bae, Seoul
How to investigate patients with ICH? (13 + 2 min)
Mia von Euler, Stockholm
BP management and ICH (13 + 2 min)
Hyung-Min Kwon, Seoul
Surgical management of spontaneous ICH from a Korean perspective (13 + 2 min)
Jeong Eun Kim, Seoul
Surgical management of spontaneous ICH from a Nordic perspective (13 + 2 min)
Ola G Nilsson, Lund
General discussion (15 min)
10
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
PROGRAM - WEDNESDAY 26 AUGUST
Sal 2
Sal 1
Sal 3
15.30-16.00 Coffe break
16.00-17.30 Teaching course 1 Free communications
Chairs: Grethe Andersen,
Chairs: Markku
Aarhus; Per Wester, Umeå
Kaste, Helsinki
O01 - A follow-up on persons
Thrombolysis:
5 years after subarachnoid
Which patients
hemorrhage (10 + 5 min)
should be
Lovisa Carlsson, Göteborg
treated?
O02 - Diabetes Mellitus and
(40 + 5 min)
Peter Sandercock, Spontaneous Intracerebral
Hemorrhage: Clinical
Edinburgh
Features and Mortality
(10 + 5 min)
Stroke mimics
Ron Liebkind, Helsinki
(40 + 5 min)
Heinrich Mattle, O03 - High sensitivity-CRP Bern
a bio-marker in stroke
sub-types? (10 + 5 min)
Lotta Larsson, Herlev
O04 - Clinical genetic testing
for monogenic ischemic
stroke in the age of next
generation sequencing
(10 + 5 min)
Andreea Ilinca, Malmö
O05 - Outcome and
complications after iv.
thrombolysis in women and
men over 80 (10 + 5 min)
Christine Kremer, Malmö
O06 - Etiology of ischemic
stroke in young Estonian
patients (10 + 5 min)
Janika Kõrv, Tartu
Workshop: Stroke rehabilitation
Chairs: Christina Brogårdh, Lund;
Bent Indredavik, Trondheim
A comparison of stroke
rehabilitation in Latvia and
Sweden (20 + 4 min)
Guna Berzina, Riga
Home-based rehabilitation for
stroke inpatients can reduce
disability and improve quality of
life (20 + 4 min)
Rune Skovgaard Rasmussen,
Copenhagen
Early Supported Discharge:
outcomes, organization and cost
effectiveness
(20 + 4 min)
Lena von Koch, Stockholm
Importance of maintaining
exercise and training after stroke
(20 + 4 min)
Birgitta Langhammer, Oslo
Sal 1
17.35-18.35 Satellite symposium:
Recent advances in stroke therapy
Sponsored by Medtronic
Chair: Nils Wahlgren, Stockholm
Intermittent Pneumatic Compression for DVT prevention – the CLOTS3 trial (18 +
2 min)
Peter Sandercock, Edinburgh
Acute ischemic Stroke, Endovascular Treatment Update following the recent
clinical data (18 + 2 min)
Tommy Andersson, Stockholm
Detection and Evaluation of ”silent” Atrial Fibrillation in Patients with Cryptogenic
Stroke (18 + 2 min)
Derk Krieger, Copenhagen
19.00-21.00 Welcome reception and exhibition at Malmö Mässan
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
11
EXHIBITON
& FLOOR27PLAN
PROGRAMAREA
- THURSDAY
AUGUST
Sal 1
Sal 3
08.30-10.00 Free communications
Chairs: Per Olof Hansson, Gothenburg; Christine
Kremer, Malmö
O07 - Quantitative Interpretation of White
Matter Hyperintensity Using Statistical Maps
(10 + 5 min)
Dong-Eog Kim, Goyang
O08 - Reproducibility of repeated endothelial
function measurements using a digital
plethysmographic technique (10 + 5 min)
Aina Støttrup Hansen, Herlev
O09 - The value of arterial transit artifact with
arterial spin labeling MRI in patients with
internal carotid artery stenosis (10 + 5 min)
Hyunkoo Kang, Seoul
O10 - Treatment of fatigue after stroke with
modafinil - a randomized, placebo controlled
trial. (10 + 5 min)
Mai Bang Poulsen, Herlev
O11 - Motor function recovery in patients with
ischemic versus hemorrhagic stroke during the
first year (10 + 5 min)
Hanna Persson, Göteborg
O12 - Work-aged stroke survivors’ short time
and long term psychosocial challenges and
follow-up needs (10 + 5 min)
Randi Martinsen, Elverum
10.00-10.30
Workshop: Stroke in the young
Chairs: Jukka Putaala, Helsinki;
Halvor Naess, Bergen
Ischemic stroke risk factors and
subtypes in the young
(20 + 4 min)
Jukka Putaala, Helsinki
Uncommon causes, how to
identify and diagnose
(20 + 4 min)
Katarina Jood, Gothenburg
Stroke in the young from an
East Asian perspective
(20 + 4 min)
Jong Sung Kim, Seoul
Prognosis and long term
outcome (20 + 4 min)
Halvor Naess, Bergen
Coffe break
Sal 1
10.30-12.00 Plenary session
Current situation in Acute stroke care and TIA management in the Nordic
Countries
Chairs: Sören Paaske Johnsen; Aarhus; Bo Norrving, Lund
Denmark (Sören Paaske Johnsen, Aarhus) (13 + 2 min)
Finland (Tiina Sairanen, Helsinki) (13 + 2 min)
Norway (Bent Indredavik, Trondheim) (13 + 2 min)
Sweden (Bo Norrving, Lund) (13 + 2 min)
Lithuania (Dalius Jatusiz, Vilnius) (13 + 2 min)
General discussion (15 min)
12.00-12.30 General assembly of Nordic Stroke Society
12.30-14.00 Lunch
Satellite symposium: 12:55-13:55
New advances in OAC treatment in AF
Sponsored by Boehringer Ingelheim
Chairs: Ann-Charlotte Laska, Stockholm; Pyotr Platonov, Lund
Acute management of stroke during OAC therapy (30 + 3 min)
Karin Klijn, Nijmegen
Emergency treatment of ICH during OAC treatment (15 +2 min)
Dorte Damgaard, Aarhus
General discussion (10 min)
12
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
PROGRAM - THURSDAY 27 AUGUST
Sal 2
14.00-15.30 Teaching course 2
Sal 1
Free communications
Chairs: Bo Norrving,
Lund
Chairs: Bent Indredavik,
Trondheim; Tiina Sairanen,
Helsinki
Brainstem syndromes O13 - Warfarin persistence
(40 + 5 min)
among atrial fibrillation
Jong Sung Kim, Seoul patients - why is treatment
ended? (10 + 5 min)
Fredrik Björck, Sundsvall
Transcranial
Color-Coded Duplex
O14 - Acute Intensive
Sonography- an
Blood Pressure-Lowering
Treatment in Patients with
introduction and
overview (20 + 2 min) Intracerebral Hemorrhage
(10 + 5 min)
Christine Kremer,
Juliane Zickert, Aarhus
Malmö
O15 - Improving logistics
for acute ischaemic stroke
TCCS monitoring of
(10 + 5 min)
systemic thrombolysis treatment
Claus Z. Simonsen, Aarhus
in acute stroke
O16 - Concurrent Holter
(20 + 3 min)
monitoring and thumbFabienne Perren,
ECG for detection of
Géneve
atrial fibrillation in stroke
patients- which is best?
(10 + 5 min)
Mai Bang Poulsen, Herlev
O17 - Predictors of Clinical
Outcome in Ischemic Stroke
Patients Treated With
Intravenous Thrombolysis
Based on Magnetic
Resonance Imaging
(10 + 5 min)
Marie Louise Schmitz,
Aarhus
15.30-16.15
16.15-17.30
19.30-
Sal 3
Workshop: Team based
stroke care
Chairs: Ann Cathrin Jönsson,
Lund; Susanne Zielke
Schaarup, Copenhagen
Initial nursing assessment
and monitoring in stroke
care (20 + 4 min)
Susanne Zielke Schaarup,
Copenhagen
Eating difficulties and
nutrition after stroke
(20 + 4 min)
Albert Westergren,
Kristianstad
Balance and cognition
post-stroke (20 + 4 min)
Marie H. Ursin, Oslo
Driving assessment after
stroke (20 + 4 min)
Helena Selander, Göteborg
Coffe break and Poster visit
Sal 1
Plenary session
Stroke recovery and prognosis
Chairs: Janika Kõrv, Tartu; Katharina Stibrant Sunnerhagen, Göteborg
Outcome, prognosis (15 + 2 min)
Jannika Kõrv, Tartu
Experimental recovery studies (15 + 2 min)
Tadeusz Wieloch, Lund
New rehabilitation methods (15 + 2 min)
Katharina Stibrant Sunnerhagen, Göteborg
Pharmacological treatment overview and special emphasis on SSRI treatment
(15 + 2 min)
Janne Keergard Mortensson, Aarhus
General discussion (7 min)
Dinner at Glasklart
Bus transport at 19.15 from Malmö Mässan.
Return from Glasklart to Malmö Mässan at 22.15 and 22.45.
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
13
EXHIBITON
AREA
& FLOOR
PLAN
PROGRAM
- FRIDAY
28 AUGUST
Sal 1
08.30-10.00 Free communications
Chairs: Evija Miglane, Riga; Katharina Stibrant
Sunnerhagen, Göteborg
O18 - The Shape/Texture Identification test (STItestTM): a reliable measure of active touch after
stroke (10 + 5 min)
Elisabeth Ekstrand, Malmö
O19 - Basic body awareness therapy in persons
with stroke: experiences among patients and
physiotherapists (10 + 5 min)
Mialinn Arvidsson Lindvall, Örebro
O20 - A multicenter study on transfer, walking and
stair climbing in persons with stroke (10 + 5 min)
Birgitta Langhammer, Oslo
O21 - New aerob exercise test: Good in stroke?
(10 + 5 min)
Rikke Steen Krawcyk, Herlev
O22 - Promoting psychosocial wellbeing following
stroke using narratives and guided
self-determination: a feasibility study (10 + 5 min)
Marit Kirkevold, Oslo
O23 - Long-term predictors for participation in social
and leisure activities ten years after stroke.
(10 + 5 min)
Anna Norlander, Lund
10.00-10.30 Coffe break
Sal 3
Workshop: Ischemic
stroke risk factors and
secondary prevention
Chairs: Eivind Berge, Oslo;
Per Wester, Umeå
Carotid artery disease
(20 + 4 min)
Per Wester, Umeå
Risk factors (20 + 4 min)
Riina Vibo, Tartu
Secondary prevention
(20 + 4 min)
Eivind Berge, Oslo
Small vessel disease
(20 + 4 min)
Susanna Melkas, Helsinki
Sal 1
10.30-12.00 Plenary session
Heart and brain: Diagnosis and management
Chairs: Hanne Christensen, Copenhagen; Jesper Petersson, Lund
Diagnostics and monitoring (15 + 2 min)
Hanne Christensen, Copenhagen
Secondary prohylaxis following cardiac causes of stroke (15 + 2 min)
Karsten Overgaard, Copenhagen
Stroke in patients treated with NOAC or Warfarin (15 + 2 min )
Jesper Petersson, Lund
Anticoagulation to AF patients with ICH on OAC treatment (7 + 2 min)
Karin Klijn, Nijmegen
Heart and cryptogenic stroke (15 + 2 min)
Arne Lindgren, Lund
General discussion (13 min)
12.00-12.30 Nordic stroke award lecture
Treatment of Acute Ischaemic Stroke: We are - perhaps - at the end of the
beginning
Nils Wahlgren, Stockholm
12.30-12.45 Farewell
Arne Lindgren, Lund
New incoming congress representatives
TBD
Dalius Jatuzis, Vilnius
12.45Lunch grab and go
14
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
Quality for life
Vi har haft som mission under nio decennier
att hjälpa människor att återställa och förbättra
sin rörlighet och självständighet. Utifrån ett
noggrant kvalitetsarbete, avancerad teknik och
nära samarbeten med patienter, sjukvård och
branschorganisationer vill vi bidra till ett
samhälle med fokus på livskvalitet. För alla.
Via vårt dotterbolag Aktiv Ortopedteknik driver
vi idag ortopedtekniska center över hela Sverige.
Vi tar emot landstingspatienter såväl som
privatpersoner som är i behov av hjälpmedel
för en aktivare vardag. Välkommen.
ottobock.se
Till patienter med icke-valvulärtförmaksflimmer:
Xarelto® 15/20 mg – enda NOAK där produktresumé på Fass.se
ger stöd för både initiering och fortsatt behandling vid
KON
RTERING
Xarelto (rivaroxaban), antitrombotiskt medel, ℞ (B01 AF01). Tabletter
15 mg, 20 mg. Indikationer: 15 mg och 20 mg: Förebyggande av stroke
och systemisk embolism hos vuxna patienter med icke-valvulärt förmaksflimmer med en eller flera riskfaktorer, såsom hjärtsvikt, hypertoni, ålder
≥ 75 år, diabetes mellitus, tidigare stroke eller transitorisk ischemisk attack (F). Behandling av djup ventrombos (DVT) och lungemboli (LE), och
förebyggande av återkommande DVT och LE hos vuxna (F). Dosering:
Förebyggande av stroke och systemisk embolism: rekommenderad dos är
20 mg en gång dagligen, vilket också är den rekommenderade maxdosen. Behandling av DVT och LE och förebyggande av återkommande DVT
och LE: rekommenderad dos för initial behandling av akut DVT eller LE är
15 mg två gånger dagligen under de första tre veckorna, följt av 20 mg
en gång dagligen för fortsatt behandling och förebyggande av återkommande DVT och LE. Särskilda patientpopulationer: För patienter med
måttligt (kreatininclearance 30–49 ml/min) eller svårt (kreatininclearance
15–29 ml/min) nedsatt njurfunktion gäller följande doseringsrekommendationer: Vid förebyggande av stroke och systemisk embolism hos patienter
med icke-valvulärt förmaksflimmer är den rekommenderade dosen 15 mg
en gång dagligen. Vid behandling av DVT och LE och förebyggande av
återkommande DVT och LE: patienterna ska behandlas med 15 mg två
gånger dagligen under de första tre veckorna. Därefter är den rekommenderade dosen 20 mg en gång dagligen. En sänkning av dosen från
20 mg en gång dagligen till 15 mg en gång dagligen bör övervägas om
patientens risk för blödning bedöms överstiga risken för återkommande
DVT och LE. Patienter med förmaksflimmer som genomgår konvertering:
Behandling med Xarelto kan initieras eller fortskrida hos patienter som
kan behöva konvertering. Kontraindikationer: Överkänslighet mot den
aktiva substansen eller mot något hjälpämne som anges i avsnitt 6. Aktiv,
kliniskt signifikant blödning. Organskada eller tillstånd, som anses utgöra
en ökad risk för större blödning. Detta kan omfatta pågående eller nyliga
ulcerationer i magtarmkanalen, förekomst av maligna tumörer med hög
blödningsrisk, nyliga hjärn- eller ryggradsskador, nyligen genomgången
hjärn-, ryggrads- eller ögonkirurgi, nyligen genomgången intrakraniell
blödning, kända eller misstänkta esofagusvaricer, arteriovenösa missbildningar, vaskulära aneurysm eller större intraspinala eller intracerebrala
vaskulära missbildningar. Samtidig behandling med andra antikoagulantia, t.ex. ofraktionerat heparin (UFH), lågmolekylärt heparin (enoxaparin,
dalteparin etc.), heparinderivat (fondaparinux etc.), orala antikoagulantia
(warfarin, dabigatranetexilat, apixaban etc.), förutom vid byte av behandling till eller från rivaroxaban eller när UFH ges i doser som krävs för att
hålla en central ven- eller artärkateter öppen. Leversjukdom förknippad
med koagulopati och kliniskt relevant blödningsrisk inklusive cirrotiska
patienter med Child Pugh B och C. Graviditet och amning. Varningar
och försiktighet: Xarelto ska användas med försiktighet hos patienter
med kreatininclearance 15–29 ml/min. Användning av Xarelto hos patienter med kreatininclearance < 15 ml/min rekommenderas inte. Hos
flera undergrupper av patienter föreligger en ökad blödningsrisk. Dessa
patienter ska övervakas noga för tecken på blödningskomplikationer efter att behandlingen inletts. För fullständig information om varningar
och försiktighet var god se www.fass.se. Förpackningar och förmån:
15 mg: 28 tabl. (F), 42 tabl. (F), 98 tabl. (F), 100 tabl. (F). 20 mg: 28 tabl.
(F), 98 tabl. (F), 100 tabl. (F). För ytterligare information och prisuppgift var
god se www.fass.se. Datum för senaste översynen av produktresumén juli
2015. Bayer AB. Box 606. 169 26 Solna. Tel. 08-580 223 00.
▼ Detta läkemedel är föremål för utökad övervakning.
L.SE.03.2015.1598
POSTERS
Poster number and titel
Poster visit on August 27, at 15.30-16.15
P01 - Reducing Stroke Door-To-Needle Time
Peter O’Keeffe, London
P02 - Predict value of circulating vascular endothelial growth factor-1 in hypertensive
patients after acute ischemic stroke
Alexander Berezin, Zaporozhye
P03 - Polymorphisms in the serotonin transporter gene and the risk of stroke –an association
study.
Janne Kaergård Mortensen, Aarhus
P04 - Cardiovascular risk factors and TIA characteristics in 19,872 Swedish TIA patients
Jakob Ström, Örebro
P05 - Pre-stroke characteristics and stroke severity after first stroke in middle-aged men
Cecilia Bergh, Örebro
P06 - Risk factors and imaging characteristics of acute lacunar infarct and associated features
of small vessel disease in brainstem and cerebellum
Eufrozina Selariu, Malmö
P07 - The role and action of phosphodiesterase 3 in cerebral small vessel disease
Saiqa Yasmeen, Herlev
P08 - Hyperintense vessel signal on arterial spin labeling MR image in acute ischemic stroke
Dong Woo Park, Guri
P9 - Arterial spin labeling perfusion MRI for acute territorial infarct, compared with dynamic
susceptibility contrast-enhanced perfusion MRI
Dong Woo Park, Guri
P10 - Stroke Forum – a link between hospital and society
Katharina Stibrant Sunnerhagen, Gothenburg
P11 - The system organization of control in the outpatient clinics for the secondary
prevention measures of the patients after stroke in the post-hospital stage in the
separately taken industrial area with a population of over 500,000 Naberezhnye Chelny,
Tatarstan, Russia
Alfiya Godunova, Naberejnye Chelny
P12 - Incidence of Transient Ischemic Attacks in Sweden during 2011-2012. A study based on
Riksstroke’s TIA register.
Peter Appelros, Örebro
P13 - The Involving Ward Round
Lone Lundbak Mathiesen, Glostrup
16
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
POSTERS
P14 - Transient global amnesia after upper GI endoscopy without premedication: two cases
reports.
Won Tae Yoon, Seoul
P15 - Intensive treadmill training in the acute phase after ischemic stroke and standardized
activities in TIA patients measured by accelerometry
Thomas Christensen, Hillerød
P16 - Twenty years trends in mortality rate from stroke in Klaipeda
Rima Radziuviene, Palanga
P17 - Swedish version of Post-Stroke Checklist (PSC-S)
Emma Kjörk, Gothenburg
P18 - Gothenburg Very Early Supported Discharge (GOTVED) - mapping of exclusion and
dropout
Lena Rafsten, Gothenburg
P19 - Grip strength is strongly associated with upper extremity muscle weakness after stroke
Christina Brogårdh, Lund
P20 - Measurement variability of Quantitative Sensory Testing in persons with shoulder pain
after stroke
Ingrid Lindgren, Lund
P21 - Movement deficits in the ipsilesional “less-affected” upper extremity after stroke.
Stroke Arm Longitudinal study at Gothenburg University, SALGOT-study.
Eva-Lena Bustrén, Gothenburg
P22 - Locked-in syndrome in Sweden; An explorative study of persons who underwent
rehabilitation
Kajsa Svernling, Gothenburg
P23 - Promoting psychosocial wellbeing in persons with aphasia - a feasibility study
Berit A. Bronken, Elverum
P24 - Exploration of potential relationship between casemix-adjusted levels of good
functional outcomes and total inpatient days during first year after stroke in
Sweden - Results from Sveus
Ingrid Lekander, Stockholm
P25 - Casemix-adjusted comparisons of health outcomes and resource utilization first year
following a stroke in Sweden – Results from Sveus
Ingrid Lekander, Stockholm
P26 - RISCLON - Risk of Recurrent Stroke in Clopidogrel Non-responders
Charlotte Lützhøft Rath, Roskilde
P27 - Mitral E/A Ratio and Potential-Cardioembolic Stroke
Kim Yerim, Gyeonggido
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
17
NOTES
The aim of the Nordic Stroke Society is to promote research on
cerebrovascular disorders in the Nordic and Baltic countries with
special emphasis on scientific collaboration and exchange across
national borders and between professional disciplines.
The Society was founded in 1982 under the name Scandinavian Society
for Cerebrovascular Diseases. In 2005 the name was changed to Nordic
Stroke Society, and colleagues from the Baltic countries were formally
welcomed to the organisation. It is now the oldest of the regional
stroke organisations in Europe.
www.nordicstroke.org
18
18th Nordic Congress on Cerebrovascular Diseases, Malmö, Sweden, August, 2015
• Over 4 years of real
world experience1
• An FDA confirmed safety
and efficacy profile2
PRADAXA® – LIVES UP
TO THE PROMISE3, 4
What does this mean
for your next new
AF patient?
CV-15-55
Referenser: 1. FDA 19 okt 2010: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
2. Graham DJ, et al. Circulation 2015;131(2):157–64. 3. Connolly SJ, et al. N Eng J Med 2009;361:1139–51 [Erratum: N Eng J Med
2010;363:1875–6 and N Eng J Med 2014;371(15):1464–5]. 4. Larsen TB, et al. Am J Med 2014;127(7):650–6.
Prescribing information: Pradaxa® (dabigatran etexilate), anticoagulant, Rx, F. Indications: Prevention of stroke and systemic embolism
in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack
(TIA); age ≥75 years; heart failure (NYHA Class ≥II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Strengths and packages: 60 x 1 and multipack 3 x 60 x 1,
blister. Capsules 110 mg and 150 mg. Warnings and restrictions: Renal function should be assessed prior to initiation of treatment
with Pradaxa. Pradaxa should be used with caution in patients with a history of/known risk factors for myocardial infarction. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Patients with severe renal impairment (CrCL <30 ml/
min). Active clinically significant bleeding. Lesion or condition, if considered a significant risk factor for major bleeding. Spontaneous or
pharmacological impairment of haemostasis. Hepatic impairment or liver disease expected to have any impact on survival. Concomitant
treatment with systemic ketoconazole, cyclosporine, itraconazole and dronedarone. Prosthetic heart valves. For price and other information
please see www.fass.se. Date of revision of the SPC 12/2014.
Boehringer Ingelheim AB. Box 47608, SE 117 94 Stockholm, Sweden.
Phone +46 (0)8-721 21 00. Fax +46 (0)8-710 98 84.
www.boehringer-ingelheim.se
Thank’s to our
sponsors and exhibitors
GOLD SPONSORS
SPONSORS
EXHIBITORS